ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial
- 1 August 2015
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 172 (8) , 751-759
Abstract
The ABCB1 gene encodes P-glycoprotein, which limits brain concentrations of certain antidepressants. ABCB1 variation has been associated with antidepressant efficacy and side effects in small-sample studies. Cognitive impairment in major depressive disorder predicts poor treatment outcome, but ABCB1 genetic effects in patients with cognitive impairment are untested. The authors examined ABCB1 genetic variants as predictors of remission and side effects in a large clinical trial that also incorporated cognitive assessment. The authors genotyped 10 ABCB1 single-nucleotide polymorphisms (SNPs) in 683 patients with major depressive disorder treated for at least 2 weeks, of whom 576 completed 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine (all substrates for P-glycoprotein) in a large randomized, prospective, pragmatic trial. Antidepressant efficacy was assessed with the 16-item Quick Inventory of Depressive Symptomatology-Self-Rated (QIDS-SR), and side effects with a rating scale for frequency, intensity, and burden of side effects. General and emotional cognition was assessed with a battery of 13 tests. The functional SNP rs10245483 upstream from ABCB1 had a significant effect on remission and side effect ratings that was differentially related to medication and cognitive status. Common homozygotes responded better and had fewer side effects with escitalopram and sertraline. Minor allele homozygotes responded better and had fewer side effects with venlafaxine, with the better response most apparent for patients with cognitive impairment. The functional polymorphism rs10245483 differentially affects remission and side effect outcomes depending on the antidepressant. The predictive power of the SNP for response or side effects was not lessened by the presence of cognitive impairment.Keywords
This publication has 46 references indexed in Scilit:
- Brain Biopsy Findings Link Major Depressive Disorder to Neuroinflammation, Oxidative Stress, and Neurovascular Dysfunction: A Case ReportBiological Psychiatry, 2014
- The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopramBehavioural Brain Research, 2014
- Effect of Venlafaxine and Desvenlafaxine on Drug Efflux Protein Expression and Biodistribution In VivoJournal of Pharmaceutical Sciences, 2013
- Blood–brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoproteinEuropean Neuropsychopharmacology, 2010
- Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysisBreast Cancer Research and Treatment, 2010
- Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated PatientsBiological Psychiatry, 2010
- Pharmacodynamics in Older Adults: A ReviewThe American Journal of Geriatric Pharmacotherapy, 2007
- Standardized assessment of cognitive functioning during development and aging using an automated touchscreen batteryArchives of Clinical Neuropsychology, 2006
- Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C]verapamil and positron emission tomographyClinical Pharmacology & Therapeutics, 2006
- Pharmacokinetics of the newer antidepressants: Clinical relevanceThe American Journal of Medicine, 1994